本帖最后由 老马 于 2012-1-13 21:20 编辑
: T0 w$ l& o7 Z+ l/ E
( p/ L8 j7 r2 D爱必妥和阿瓦斯丁的比较
# h. @" I8 d% y' W5 l O3 S
" h x1 a# ~+ {" Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: d/ X/ G* b$ |# U- z
2 [( k6 ~: }0 v, ^9 L
, ]! g+ U8 h/ L, b) w: x1 s3 ^
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ \7 I% a- a8 b* I9 E==================================================
- t R2 k0 S0 M8 s/ Y5 kOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): S8 @" A3 Z }! y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( W7 R7 M7 }0 T: r: F& vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ S2 S6 q2 X1 r
|